A
A

Price • Avalo Therapeutics

AVTX

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo’s pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Historical stock price chart and annual return over the past years

-100%

5 years

% Total

AVTX
-73%

5 years

Annual Return

AVTX